Invet Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.25 M
- Paid Up Capital ₹ 1.25 M
- Company Age 12 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.50 M
- Revenue Growth %
- Profit Growth -7.94%
- Ebitda -3.15%
- Net Worth -26.29%
- Total Assets -0.08%
About Invet Pharma
Invet Pharma Private Limited (IPPL) is a Private Limited Indian Non-Government Company incorporated in India on 13 June 2012 and has a history of 12 years and seven months. Its registered office is in Agra, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.25 M and a paid-up capital of Rs 1.25 M.
The company currently has active open charges totaling ₹4.50 M.
Swatantra Jain and Suresh Chandra serve as directors at the Company.
Company Details
-
Location
Agra, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24233UP2012PTC050975
-
Company No.
050975
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
13 Jun 2012
-
Date of AGM
25 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Invet Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Swatantra Jain
|
Director | 13-Jun-2012 | Current |
|
Suresh Chandra
|
Director | 29-Apr-2016 | Current |
Financial Performance of Invet Pharma.
Invet Pharma Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a slight decrease in profitability, with a 7.94% decrease in profit. The company's net worth observed a substantial decline by a decrease of 26.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Invet Pharma?
In 2023, Invet Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹4.50 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.45 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 05 Jul 2016 | Others | ₹4.50 M | Open |
How Many Employees Work at Invet Pharma?
Unlock and access historical data on people associated with Invet Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Invet Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Invet Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
